Investigational New Drugs

, Volume 19, Issue 2, pp 113–123

Determinants of Paclitaxel Uptake, Accumulation and Retention in Solid Tumors

  • Seong H. Jang
  • M. Guillaume Wientjes
  • Jessie L.-S. Au
Article

Abstract

This report addresses the determinants ofthe rate and extent of paclitaxelaccumulation in tumors. In a 2-dimensionalsystem such as monolayers where the drug isdirectly in contact with tumor cells, drugaccumulation is determined by theextracellular-to-intracellularconcentration gradient, the drug binding toextracellular and intracellularmacromolecules, the presence of the mdr1p-glycoprotein (Pgp), and thetime-dependent and drugconcentration-dependent changes in tubulinsand cell density. Intracellularpharmacokinetic models were developed todepict the effects of these parameters.Computer simulation results indicate thatat the clinically relevant concentrationrange of 1 to 1,000 nM, (a) the bindingaffinity and the number of intracellularsaturable drug binding sites are importantfor drug accumulation at low and highextracellular concentrations, respectively,(b) saturation in the drug binding to thehigh affinity intracellular binding sites(e.g., tubulin/microtubule) occurs atextracellular drug concentration above 100nM, (c) treatment with 1,000 nM paclitaxelfor ≥4 hr results in increased levels oftubulin/microtubule and consequentlyincreased intracellular drug accumulation,whereas the continued cell proliferationafter treatment with low drugconcentrations results in reducedintracellular accumulation, and (d)saturation of Pgp in mdr1-transfectedcells occurs at the high end of theclinically relevant concentration range. Ina 3-dimensional system such as the solidtumor histocultures, which contain tumorcells as well as stromal cells, the drugaccumulation into the inner cell layers isdetermined by the unique properties ofsolid tumors, including tumor cell densityand spatial arrangement of tumor andstromal tissues. Most interestingly, drugpenetration is modulated by thedrug-induced apoptosis; the reduced celldensity due to apoptosis results in anenhancement of the rate of drug penetrationinto the inner cell layers of solid tumors.In conclusion, the uptake, accumulation,and retention of paclitaxel in solid tumorsare determined by (a) factors that areindependent of biological changes in tumorcells induced by paclitaxel, i.e., ratio ofextracellular and intracellularconcentrations, and drug binding toextracellular and intracellularmacromolecules, and (b) factors that aredependent on the time- and drugconcentration-dependent biological changesinduced by paclitaxel, i.e., induction ofapoptosis, enhancement oftubulin/microtubule production, andinduction of Pgp expression.

paclitaxel uptake efflux penetration apoptosis solid tumor histoculture 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rowinsky EK, Wright M, Monsarrat B, Lesser GJ, Donehower RC: Taxol: Pharmacology, metabolism and clinical implications. Cancer Surveys 17: 283–301, 1993PubMedGoogle Scholar
  2. 2.
    Lopes NM, Adams EG, Pitts TW, Bhuyan BK: Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32: 235–242, 1993PubMedGoogle Scholar
  3. 3.
    Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, Ponnathpur V, Tourkina E, Ibrado AM, Bullock G, Willingham MC: Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia8: 465–475, 1994PubMedGoogle Scholar
  4. 4.
    Jekunen AP, Christen RD, Shalinsky DR, Howell SB: Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69: 299–306, 1994PubMedGoogle Scholar
  5. 5.
    Riou JF, Retitgenet O, Combeau C, Lavelle F: Cellular uptake and efflux of docetaxel (taxotere) and paclitaxel (taxol) in P388 cell line. Proc Am Assoc Cancer Res 35: 160, 1994Google Scholar
  6. 6.
    Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD, Tew KD: P-glycoprotein binding and modulation of the multidrug resistant phenotype by estramustine. J Natl Cancer Inst 86: 688–694, 1994PubMedGoogle Scholar
  7. 7.
    Jamis-Dow CA, Klecker RW, Sarosy G, Reed E, Collins JM: Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33: 48–52, 1993PubMedGoogle Scholar
  8. 8.
    Longnecker SM, Donehower RC, Cates AE, Chen TL, Brundrett RB, Grochow LB, Ettinger DS, Colvin M: Highperformance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71: 53–59, 1987PubMedGoogle Scholar
  9. 9.
    Song D, Hsu LF, Au JLS: Binding of taxol to plastic and glass containers and proteins under in vitro conditions. J Pharm Sci 85: 29–31, 1996PubMedGoogle Scholar
  10. 10.
    Nicholson KM, Bibby MC, Phillips RM: Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. Eur J Cancer 33: 1291–1298, 1997PubMedGoogle Scholar
  11. 11.
    Durand RE: Slow penetration of anthracyclines into spheroids and tumors: a therapeutical advantage? Cancer Chemother Pharmacol 26: 198–204, 1990PubMedGoogle Scholar
  12. 12.
    Erlanson M, Daniel-Szolgay E, Carlsson J: Relationship between the penetration, binding and average concentration of cytostatic drugs in human tumor spheroids. Cancer Chemother Pharmacol 29: 343–353, 1992PubMedGoogle Scholar
  13. 13.
    Baguley BC, Finlay GJ: Pharmacokinetic/cytokinetic principles in the chemotherapy of solid tumours. Clin Exp Pharmacol Physiol 22: 825–828, 1995PubMedGoogle Scholar
  14. 14.
    Nederman T, Carlsson J: Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol 13: 131–135, 1984PubMedGoogle Scholar
  15. 15.
    Kuh HJ, Jang SH, Wientjes MG, Au JLS: Computational model of intracellular pharmacokinetics of paclitaxel. J Pharmacol Exp Ther 293: 761–770, 2000PubMedGoogle Scholar
  16. 16.
    Manfredi JJ, Parness J, Horwitz SB: Taxol binds to cellular microtubules. J Cell Biol 94: 688–696, 1982PubMedGoogle Scholar
  17. 17.
    Jordan MA, Toso RJ, Thrower D, Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Nat Acad Sci USA 90: 9552–9556, 1993PubMedGoogle Scholar
  18. 18.
    Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson, L: Mitotic block induced in HeLa cells by low con123 centrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816–825, 1996PubMedGoogle Scholar
  19. 19.
    Jang SH, Kuh HJ, Wientjes MG, Au JLS: Kinetics and mathematical modeling of paclitaxel efflux by p-glycoprotein in BC19 cells. Proc Am Assoc Cancer Res 39: 218, 1998Google Scholar
  20. 20.
    Bradley G, Ling V: P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 13: 223–233, 1994PubMedGoogle Scholar
  21. 21.
    Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385–427, 1993CrossRefPubMedGoogle Scholar
  22. 22.
    Furukawa T, Kubota T, Hoffman RM: The clinical applications of the histoculture drug response assay. Clin Cancer Res 1: 305–311, 1995PubMedGoogle Scholar
  23. 23.
    Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Demura H, Sasano H, Nagura H, Ogawa N, Hoffman R, the Chemosensitivity Study Group for the Histoculture Drug-Response Assay: Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1: 1537–1543, 1995PubMedGoogle Scholar
  24. 24.
    Robbins KT, Connors KM, Storniolo AM, Hanchett C, Hoffman RM: Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Arch Otolaryngol Head Neck Surg 120: 288–292, 1994PubMedGoogle Scholar
  25. 25.
    Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB: Altered expression of M_2, the class II_-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 270: 31269–31275, 1995PubMedGoogle Scholar
  26. 26.
    Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI: Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56: 1091–1097, 1996PubMedGoogle Scholar
  27. 27.
    Dumontet C, Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061–1070, 1999PubMedGoogle Scholar
  28. 28.
    Parness J, Horwitz SB: Taxol binds to polymerized tubulin in vitro. J Cell Biol 91: 479–487, 1981PubMedGoogle Scholar
  29. 29.
    Au JLS, Li D, Gan Y, Gao X, Johnson AL, Johnston J, Millenbaugh NJ, Jang SH, Kuh, HJ, Chen CT, Wientjes MG: Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res 58: 2141–2148, 1998PubMedGoogle Scholar
  30. 30.
    Fairchild CR, Moscow JA, O'Brien EE, Cowan KH:Multidrug resistance in cells transfected with human genes encoding a variant p-glycoprotein and glutathione S-transferase-—. Mol Pharmacol 37: 801–809, 1990PubMedGoogle Scholar
  31. 31.
    Li D, Koo KL, Au JLS: P-glycoprotein overexpression increases maximum induction of apoptosis by taxol. Proc Am Assoc Cancer Res 39: 217, 1998Google Scholar
  32. 32.
    Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JLS: Determinants of paclitaxel penetration and accumulation in human solid tumor.J Pharmacol Exp Ther 290: 871–880, 1999PubMedGoogle Scholar
  33. 33.
    Kang HJK., Tran AQ, Wientjes MG, Au JLS: A kinetic model for taxol accumulation in human cancer cells: In vivo extrapolation. Proc Am Assoc Cancer Res 38: 604, 1997Google Scholar
  34. 34.
    Cheng L, Zheng S, Raghunathan K, Priest DG, Willingham MC, Norris JS, Fan, W: Characterisations of taxol-induced apoptosis and altered gene expression in human breast cancer cells. Cell Pharmacol 2: 249–257, 1995Google Scholar
  35. 35.
    Milas L, Hunter NR, Kurdoglu B, Mason KA, Meyn RE, Stephens LC, Peters LJ: Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol 35: 297–303, 1995PubMedGoogle Scholar
  36. 36.
    Saunders DE, Lawrence WD, Christensen C, Wappler NL, Ruan H, Deppe G: Paclitaxel-induced apoptosis in MCF7 breast cancer cells. Int J Cancer 70: 214–220, 1997PubMedGoogle Scholar
  37. 37.
    Gan Y, Wientjes MG, Schuller DE, Au JLS: Pharmacodynamics of taxol in human head and neck tumors. Cancer Res 56: 2086–2093, 1996PubMedGoogle Scholar
  38. 38.
    Au JL, Kumar RR, Li D, Wientjes MG: Kinetics of hallmark biochemical changes in paclitaxel-induced apoptosis. AAPS PharmSci. 1: article 8, 1999(http: //www.pharmsci.org/journal)Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Seong H. Jang
    • 1
  • M. Guillaume Wientjes
    • 1
  • Jessie L.-S. Au
    • 1
  1. 1.College of PharmacyThe Ohio State UniversityColumbusUSA

Personalised recommendations